Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBT Margin: 2010-2025

Historic EBT Margin for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to 55.73%.

  • Ironwood Pharmaceuticals' EBT Margin rose 3676.00% to 55.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.66%, marking a year-over-year increase of 9861.00%. This contributed to the annual value of 47.55% for FY2024, which is 31285.00% up from last year.
  • Ironwood Pharmaceuticals' EBT Margin amounted to 55.73% in Q3 2025, which was up 25.59% from 44.37% recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBT Margin ranged from a high of 139.03% in Q4 2024 and a low of -1,002.24% during Q2 2023.
  • Its 3-year average for EBT Margin is -80.11%, with a median of 20.00% in 2024.
  • Its EBT Margin has fluctuated over the past 5 years, first slumped by 105,755bps in 2023, then skyrocketed by 102,223bps in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBT Margin (Quarterly) stood at 39.49% in 2021, then spiked by 2,792bps to 67.41% in 2022, then tumbled by 23,429bps to -166.88% in 2023, then skyrocketed by 30,591bps to 139.03% in 2024, then surged by 3,676bps to 55.73% in 2025.
  • Its EBT Margin stands at 55.73% for Q3 2025, versus 44.37% for Q2 2025 and -88.16% for Q1 2025.